Frontiers in Oncology (Jul 2018)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma

  • Shigehisa Kitano,
  • Shigehisa Kitano,
  • Takayuki Nakayama,
  • Makiko Yamashita

DOI
https://doi.org/10.3389/fonc.2018.00270
Journal volume & issue
Vol. 8

Abstract

Read online

Immune checkpoint inhibitors have now become a standard therapy for malignant melanoma. However, as immunotherapies are effective in only a limited number of patients, biomarker development remains one of the most important clinical challenges. Biomarkers predicting clinical benefit facilitate appropriate selection of individualized treatments for patients and maximize clinical benefits. Many biomarkers derived from tumors and peripheral blood components have recently been reported, mainly in retrospective settings. This review summarizes the recent findings of biomarker studies for predicting the clinical benefits of immunotherapies in melanoma patients. Taking into account the complex interactions between the immune system and various cancers, it would be difficult for only one biomarker to predict clinical benefits in all patients. Many efforts to discover candidate biomarkers are currently ongoing. In the future, verification, by means of a prospective study, may allow some of these candidates to be combined into a scoring system based on bioinformatics technology.

Keywords